Home > Technical section > Immunochemistry > IHC techniques > PD-L1 study
PD-L1 study
Monday 31 October 2016
PD-L1 IHC; PD-L1 immunochemistry
Indications
VENTANA PD-L1 assay (SP142 assay)
- before atezolizumab (TECENTRIQ®) treatment
- previously treated metastatic non-small cell lung carcinoma (NSCLC )
- urothelial carcinoma
non-small cell lung cancer (NSCLC)
- Predictive PD-L1 immunohistochemistry for non-small cell lung cancer
Antibodies
Ventana SP142
Ventana SP263
Cell signaling E1L3N
Dako 22C3 PharmDx
Dako 28-8 PharmDx
News
Open references
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. Sun WY, Lee YK, Koo JS. J Transl Med. 2016 Jun 10;14(1):173. doi : 10.1186/s12967-016-0925-6 PMID: 27286842 (Free)
Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ. Oncotarget. 2015 Aug 14;6(23):19819-25. PMID: 26110571 Free
